Invo reports $1.38 million in quarterly sales, representing a 396.15% increase over sales of $278,140 from the same period last year. The company says it remains on-track with its goal of reaching ...

The Details: Invo BioScience said the combined company will continue to operate its fertility business as well as expand its focus to the development of clinical-stage assets in oncology and ...

Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued ...

INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024 Experienced, entrepreneurial leadership team to help structure merged public ...

SARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience (INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing patient access to ...

Valued at less than $54 million in market capitalization, and with total annual sales barely passing the $1 million mark, Sarasota, Florida-based INVO Bioscience (INVO) is hardly a household name -- ...

Post-merger, the combined company, operating under the name "NAYA Biosciences", will be dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative ...

Beverly-based Invo Bioscience Inc. is looking to address a serious problem — infertility — by implementing a notably offbeat strategy using the public finance market. Last Friday, Invo went public ...

BEVERLY, Mass.--(BUSINESS WIRE)--INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced that INVO Bioscience ...